Table 3 Treatment-related prognosis predictors of patients with GBS
From: Prognostic factors of Guillain-Barré syndrome: a 111-case retrospective review
Number of patients(%) | MRC score at discharge | Comparison* (P-value) | |
|---|---|---|---|
Treatment | 0.975 | ||
IVIg | 40 (36.04%) | 32.41±14.330 | |
IVIg plus glucocorticoid | 57 (51.25%) | 33.63±8.557 | |
Treatment | 0.175 | ||
IVIg | 40 (36.04%) | 32.41±14.330 | |
Glucocorticoid | 11 (9.91%) | 37.55±3.616 | |
Duration between onset and treatment | 0.181 | ||
Less than 7 days | 55 (49.55%) | 32.22±10.906 | |
7 to 14 days | 30 (27.03%) | 33.43±10.897 | |
More than 14 days | 23 (20.72%) | 35.61±7.316 |